[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 22 of about 22
1. Yoshikawa H, Nakamoto Y, Ozawa T, Dickinson RM: A dog with osteosarcoma which metastasized to the eye months before metastasis to other organs. J Vet Med Sci; 2008 Aug;70(8):825-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A dog with osteosarcoma which metastasized to the eye months before metastasis to other organs.
  • A 9-year-old male Shih Tzu with osteosarcoma had a forelimb amputation and underwent chemotherapy.
  • During chemotherapy, the right eye was enucleated due to refractory glaucoma, and was diagnosed as anterior uveal malignant melanoma.
  • The dog lived for 4 months after the enucleation without treatment.
  • After the dog died, the mass in the eye was re-evaluated immunohistochemically, and it was diagnosed as metastasis of appendicular osteosarcoma.
  • Metastasis of appendicular osteosarcoma to the anterior chamber is quite rare, and the clinical course which showed clinically detectable metastases to the eye before systemic multi-organ metastases was quite unique.

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18772558.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


2. Pérez-Fidalgo JA, Vila Arteaga J, Chirivella González I, Martínez Belda R, Bermejo de Lasheras B, Roselló Keranën S, Fons Moreno A, Lluch Hernández A: [Breast cancer metastases in the iris: does treatment modifies natural history of the illness?]. An Med Interna; 2008 Apr;25(4):178-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Breast cancer metastases in the iris: does treatment modifies natural history of the illness?].
  • [Transliterated title] Metástasis en iris de un carcinoma de mama: ¿modifica el tratamiento la historia natural de la enfermedad?
  • The 4-5% of the breast cancer patients have metastases in the eye.
  • Six months after primary radical treatment she had a systemic relapse with multiples metastatic sites, so several treatment with trastuzumab in combination with chemotherapy were started.
  • After 4 years patient presented multiple white-coloured micronodules in the iris of the right eye.
  • Only a 3-7.8% of ocular metastases are located in the iris.
  • With mantenaince therapy with trastuzumab natural history of the illness has changed.
  • Several studies had analyzed if metastases in the brain during treatment with trastuzumab have increased in comparison with the pretrastuzumab era.
  • The infrequent presentation of metastases in the anterior uveal makes difficult to establish if it is an spontaneous fact or if it is favoured by trastuzumab treatment.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / secondary. Iris Neoplasms / secondary


3. Liu J, Liu G, Xu G, Chen L, Liang Y: [Concomitant whole brain radiotherapy and FUDR+VM-26+DDP chemotherapy in brain metastasis of non-small cell lung cancer: a report of short term efficacy]. Zhongguo Fei Ai Za Zhi; 2003 Oct 20;6(5):371-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Concomitant whole brain radiotherapy and FUDR+VM-26+DDP chemotherapy in brain metastasis of non-small cell lung cancer: a report of short term efficacy].
  • BACKGROUND: To evaluate the efficacy and toxicity of concomitant chemoradiotherapy in patients with brain metastases from non-small cell lung cancer (NSCLC).
  • METHODS: Thirty patients suffering from NSCLC with brain metastasis were prospectively included in this study.
  • Treatment consisted of concomitant whole brain radiotherapy (WBRT) with a dose of 30 Gy in 15 fractions, followed by a local boosted dose of 20 Gy in 10 fractions for those that the number of the remained lesions were less than 3, or by WBRT with a total dose of 50 Gy for those that the number of the remained lesions were more than 3.
  • Concomitant chemotherapy of FVP regimen with floxuridine 600 mg/(m²*d), teniposide 60 mg/(m²*d), cisplatin 20 mg/(m²*d) on d1 to d5,repeating every 3 or 4 weeks.
  • The response was evaluated by brain CT or MRI after WBRT and 2 cycles of chemotherapy being completed.
  • RESULTS: All the patients completed WBRT and concomitant chemotherapy including 68 cycles (2 to 4 cycles for each patient).
  • Other specific evaluation of metastases included 1 PR patient in 6 patients with lung metastases, 3 CR patients and 4 PR patients in 17 patients with lymph node metastases, 1 PR patient with liver metastases, and 1 PR patient with eye metastasis.
  • Dehydration therapy was needed at 2 weeks after WBRT in all patients.
  • CONCLUSIONS: Concomitant WBRT plus FUDR+VM-26+DDP chemotherapy is tolerable in NSCLC patients with brain metastases and the short term response is comparable to the results of others.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21306682.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


Advertisement
4. Süveges I: [Intraocular tumours]. Magy Onkol; 2005;49(1):9-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intraocular tumours may be benign or malignant.
  • The more malignant growths are those which are situated closer to the posterior pole.
  • Histologically the epitheloid cell-type of melanoma is more malignant than those containing only spindle cells.
  • Their treatment depends on the size: in the case of large tumours enucleation is required, while for the smaller ones, radiation therapy can be applied.
  • Sixty-seven percent of the inherited-type cases are bilateral.
  • A white tissue mass growing into the vitreous is seen on the fundus.
  • Histologically the tumour contains malignant neuroepithelial cells, which may form a rosette.
  • In the case of large tumours the treatment is enucleation; in bilateral processes the bulbus with the larger mass is removed and the other eye is treated with radiation therapy.
  • In both cases chemotherapy is used according to a prescribed schedule.
  • Metastases to the eye occur most frequently from carcinomas of the breast, lungs or gastrointestinal tract.
  • These are treated with radiotherapy, chemotherapy and hormone therapy.
  • Some benign tumours are found by chance on routine eye examinations, others due to subjective and objective symptoms.
  • [MeSH-major] Eye Neoplasms
  • [MeSH-minor] Humans. Lymphoma / diagnosis. Lymphoma / therapy. Melanoma / diagnosis. Melanoma / therapy. Retinal Neoplasms / diagnosis. Retinal Neoplasms / therapy. Retinoblastoma / diagnosis. Retinoblastoma / therapy

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15902327.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Hungary
  • [Number-of-references] 2
  •  go-up   go-down


5. Coutts MA, Borthwick NJ, Hungerford JL, Cree IA: Post-menopausal bleeding: a rare presentation of metastatic uveal melanoma. Pathol Oncol Res; 2006;12(3):184-7
MedlinePlus Health Information. consumer health - Vaginal Bleeding.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-menopausal bleeding: a rare presentation of metastatic uveal melanoma.
  • Uveal melanoma differs from cutaneous melanoma in many ways, including its pattern of metastasis, and exhibits latency with clinical evidence of metastasis sometimes appearing many years after primary diagnosis.
  • Most patients develop metastasis within the liver, but some may present with metastasis to other sites.
  • We report a case of uveal melanoma that presented with post-menopausal bleeding due to metastasis.
  • Further investigation revealed widespread metastatic disease and the patient was not fit for chemotherapy.
  • She died two months after presentation: autopsy revealed metastases in many sites, including the uterus, right ovarian fibroma, kidney, mesentery, liver, lung, thyroid, bone marrow and skin.
  • The immediate cause of death was cardiac tamponade due to a malignant effusion secondary to cardiac metastasis.
  • This case illustrates the widespread metastatic potential of uveal melanoma and highlights the potential for unusual presentation of metastatic disease from this eye tumor.
  • [MeSH-minor] Aged, 80 and over. Endometrial Neoplasms / secondary. Female. Heart Neoplasms / secondary. Humans. Liver Neoplasms / secondary. Neoplasm Metastasis. Postmenopause

  • Genetic Alliance. consumer health - Uveal melanoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Ophthalmol (Copenh). 1970;48(6):1113-28 [5537253.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2003 Nov;44(11):4651-9 [14578381.001]
  • [Cites] Am J Ophthalmol. 1985 Nov 15;100(5):666-8 [4061546.001]
  • [Cites] Retina. 1981;1(2):100-6 [7348822.001]
  • [Cites] Gynecol Oncol. 2004 Apr;93(1):252-6 [15047246.001]
  • [Cites] Am J Ophthalmol. 1978 Oct;86(4):557-64 [707604.001]
  • [Cites] Cancer. 1982 Nov 15;50(10):2163-9 [7127256.001]
  • [Cites] J Thorac Cardiovasc Surg. 2005 Dec;130(6):1727-8 [16308029.001]
  • [Cites] Acta Ophthalmol (Copenh). 1963;43:SUPPL 75:1-220 [14050563.001]
  • [Cites] J Med Ethics. 2005 Jun;31(6):360-1 [15923487.001]
  • [Cites] J Med Ethics. 2004 Dec;30(6):561-4 [15574445.001]
  • [Cites] Ophthalmology. 1980 Jun;87(6):549-56 [7413144.001]
  • [Cites] Acta Ophthalmol (Copenh). 1982 Apr;60(2):161-82 [7136531.001]
  • [Cites] Int Ophthalmol. 1985 Mar;7(3-4):175-81 [3997359.001]
  • [Cites] Br J Ophthalmol. 1999 May;83(5):588-94 [10216060.001]
  • [Cites] Arch Ophthalmol. 1999 Nov;117(11):1558-9 [10565531.001]
  • [Cites] Cancer Invest. 1997;15(2):98-105 [9095204.001]
  • [Cites] Acta Cytol. 1978 Nov-Dec;22(6):503-6 [282750.001]
  • [Cites] Chest. 2001 Dec;120(6):2115 [11742953.001]
  • [Cites] APMIS. 1989 Nov;97(11):1018-24 [2590533.001]
  • [Cites] Cancer. 1974 Mar;33(3):729-31 [4815575.001]
  • (PMID = 16998600.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


6. Kook KH, Park MS, Yim H, Lee SY, Jang JW, Grossniklaus HE: A case of congenital orbital malignant rhabdoid tumor: systemic metastasis following exenteration. Ophthalmologica; 2009;223(4):274-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of congenital orbital malignant rhabdoid tumor: systemic metastasis following exenteration.
  • A newborn girl presented with massive proptosis of the right eye.
  • A diagnosis of malignant rhabdoid tumor was made by histopathologic examination of an incisional biopsy specimen.
  • Exenteration was performed, and the resection margins were free from tumor cells.
  • However, distant metastasis developed in the liver 1 month after surgery.
  • Despite chemotherapy, the patient died 2 months later due to tumor invasion into the central nervous system, which was confirmed by autopsy.
  • To the best of our knowledge, this is the first case of congenital orbital malignant rhabdoid tumor showing systemic metastasis after exenteration, which suggests the need for aggressive systemic treatment rather than exenteration, even in a case of locally confined tumor.

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 S. Karger AG, Basel.
  • [Cites] J AAPOS. 1999 Oct;3(5):318-20 [10532580.001]
  • [Cites] Cancer. 1978 May;41(5):1937-48 [206343.001]
  • [Cites] Hum Pathol. 1981 Jul;12(7):646-57 [7275104.001]
  • [Cites] Ophthalmology. 1989 Nov;96(11):1650-4 [2694050.001]
  • [Cites] Arch Ophthalmol. 1991 Sep;109(9):1275-8 [1656924.001]
  • [Cites] Pediatr Blood Cancer. 2006 Nov;47(6):846-50 [16534791.001]
  • [Cites] Ophthalmology. 1992 Apr;99(4):567-74 [1374874.001]
  • [Cites] Am J Surg Pathol. 1994 Oct;18(10):1010-29 [8092393.001]
  • [Cites] Arch Ophthalmol. 1998 Feb;116(2):243-6 [9488282.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2005 Jan;21(1):76-9 [15677960.001]
  • [Cites] Histopathology. 1992 Feb;20(2):170-3 [1313784.001]
  • (PMID = 19390226.001).
  • [ISSN] 1423-0267
  • [Journal-full-title] Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde
  • [ISO-abbreviation] Ophthalmologica
  • [Language] ENG
  • [Grant] None / None / / P30 EY006360-25; United States / NEI NIH HHS / EY / P30 EY006360-25
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ NIHMS239394; NLM/ PMC2988226
  •  go-up   go-down


7. Papageorgiou KI, Sinha A, Ioannidis AS, Davidson NG: Ocular metastases from HER2 positive breast carcinoma and the response to combination therapy with Paclitaxel and Trastuzumab: a case report. Cases J; 2009;2:9143
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ocular metastases from HER2 positive breast carcinoma and the response to combination therapy with Paclitaxel and Trastuzumab: a case report.
  • The mean survival period after diagnosis of metastasis to the eye, ranges from 10 to 32 months.
  • However, recent advances in therapy including the use of monoclonal antibody therapy, will hopefully improve treatment outcomes and prolong survival rates.
  • METHODS: We report a case of a 45 year old woman with a HER2 positive breast cancer, who developed two metastatic lesions in the left choroid, and the left optic nerve sheath.
  • She underwent treatment with a combination of chemotherapy (Paclitaxel) and anti-HER2 monoclonal antibodies (Trastuzumab).
  • RESULTS: Nine months after treatment, a B-scan showed resolution of the superior choroidal focus, as well as absence of blood flow within the optic nerve sheath.
  • CONCLUSION: The patient underwent a combined treatment of chemotherapy and Trastuzumab to increase the response rate.
  • Nine months following the therapy her vision was stable, whilst one focus of the tumour in the affected eye, had regressed.
  • The favourable response highlights the significant impact of this new therapy, as an alternative to external beam radiotherapy in patients with ocular metastasis from HER2 (+) breast cancer.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1659-72 [16236737.001]
  • [Cites] Am J Ophthalmol. 2003 Aug;136(2):264-71 [12888048.001]
  • [Cites] Adv Exp Med Biol. 2003;532:253-68 [12908564.001]
  • [Cites] Cancer. 1991 Aug 1;68(3):623-7 [2065283.001]
  • (PMID = 20062660.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2803940
  •  go-up   go-down


8. Talwar V, Vaid AK, Doval DC, Bhatia K, Jena A, Anand AK: Isolated intraorbital metastasis in breast carcinoma. J Assoc Physicians India; 2007 Jun;55:451-2
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated intraorbital metastasis in breast carcinoma.
  • We report a case of metastases to the eye, in a 30 year old lady with carcinoma breast leading to isolated metastatic involvement of the lateral rectus muscle with no evidence of metastases at any other site in the body after a follow up of one year after completion of chemotherapy.
  • [MeSH-major] Breast Neoplasms / pathology. Orbital Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17879503.001).
  • [ISSN] 0004-5772
  • [Journal-full-title] The Journal of the Association of Physicians of India
  • [ISO-abbreviation] J Assoc Physicians India
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


9. Schmidt-Hieber M, Schmittel A, Thiel E, Keilholz U: A phase II study of bendamustine chemotherapy as second-line treatment in metastatic uveal melanoma. Melanoma Res; 2004 Dec;14(6):439-42
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of bendamustine chemotherapy as second-line treatment in metastatic uveal melanoma.
  • Uveal melanoma is the most frequent primary malignant neoplasm of the eye and has a poor prognosis in metastatic stage.
  • Fotemustine or a combination of gemcitabine and treosulfan has demonstrated some efficacy in metastatic disease.
  • Inclusion criteria were a Karnofsky performance status of > or = 60% and progressive disease during or after first-line chemotherapy.
  • The secondary endpoint was toxicity.
  • We conclude that bendamustine is ineffective as second-line chemotherapy for metastatic uveal melanoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Melanoma / drug therapy. Nitrogen Mustard Compounds / therapeutic use. Skin Neoplasms / drug therapy. Uveal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Bendamustine Hydrochloride. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Neoplasm Staging. Salvage Therapy. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Uveal melanoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Bendamustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15577312.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Nitrogen Mustard Compounds; 981Y8SX18M / Bendamustine Hydrochloride
  •  go-up   go-down


10. Ozturk B, Buyukberber S, Coskun U, Yaman E, Yildiz R, Kaya AO, Oner Y, Benekli M: Solitary iris metastasis from breast cancer with dramatic course: case report. Med Oncol; 2007;24(4):463-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary iris metastasis from breast cancer with dramatic course: case report.
  • Intraocular metastases are the most common malignancy of eye.
  • Breast cancer is more frequently a cause of intraocular metastases.
  • As a first metastatic site, iris and ciliary body are relatively rare.
  • We report a case of a 52-year-old woman, operated for breast cancer 16 months ago and diagnosed multiple brain metastases 1 month ago.
  • After first course of chemotherapy she was admitted to hospital with the complaints of eye pain and she recognized a solid mass on iris.
  • Iris and ciliary metastases were diagnosed by ophthalmological examination.
  • Because of the patient's poor general condition, diagnostic aspiration from eye metastasis could not be performed.
  • Ciliary body and iris metastases of breast cancer must be considered as a manifestation of aggressive clinical course and poor prognosis.
  • The eye metastases of breast cancer are a part of systemic illness and must be treated by systemic chemotherapy.
  • [MeSH-major] Breast Neoplasms / pathology. Iris Neoplasms / diagnosis. Iris Neoplasms / secondary

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1991 Aug 1;68(3):623-7 [2065283.001]
  • [Cites] Ophthalmologica. 2000 Sep-Oct;214(5):368-72 [10965254.001]
  • [Cites] Med Oncol. 2004;21(3):217-21 [15456948.001]
  • [Cites] Am J Ophthalmol. 1983 Jun;95(6):788-93 [6859188.001]
  • [Cites] Ophthalmology. 1997 Aug;104(8):1265-76 [9261313.001]
  • [Cites] Am J Ophthalmol. 2003 Aug;136(2):264-71 [12888048.001]
  • [Cites] Klin Oczna. 2004;106(3):347-50 [15515324.001]
  • [Cites] Cancer Control. 1998 Jul;5(4):326-332 [10761082.001]
  • [Cites] Oncol Rep. 2000 Jul-Aug;7(4):761-5 [10854540.001]
  • [Cites] Ophthalmologe. 2006 Jan;103(1):48-51 [15538583.001]
  • [Cites] Zhonghua Yi Xue Za Zhi (Taipei). 1998 Apr;61(4):223-9 [9614781.001]
  • [Cites] Cancer Treat Rev. 1991 Dec;18(4):261-76 [1842577.001]
  • [Cites] Br J Ophthalmol. 1998 Oct;82(10):1159-61 [9924304.001]
  • (PMID = 17917101.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Okuma Y, Hosomi Y, Kitamura K, Iguchi M, Okamura T, Fukami S, Hishima T, Shibuya M: Choroidal metastasis in a patient with small cell lung cancer discovered during treatment with chemotherapy. Int J Clin Oncol; 2009 Dec;14(6):541-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Choroidal metastasis in a patient with small cell lung cancer discovered during treatment with chemotherapy.
  • He was treated with chemotherapy.
  • While undergoing treatment with chemotherapy, he complained of a right visual disturbance, and choroidal metastasis was diagnosed.
  • Because the primary site responded well to chemotherapy alone and the visual disturbance did not worsen, the patient refused radiotherapy to the choroidal metastasis.
  • Two months after the first diagnosis of the choroidal metastasis, while he was receiving the first treatment regimen for SCLC, the visual disturbance suddenly worsened; emergent radiotherapy was started, with a total dose of 40 Gy, given as 2.0 Gy/fraction per day.
  • Within 6 months of diagnosis, the patient became blind in his right eye.
  • The patient died of septic shock related to treatment received during his third chemotherapy regimen.
  • Choroidal metastasis is very rare with extraocular malignant tumors, though it is common with intraocular malignant tumors.
  • Choroidal metastasis secondary to SCLC has a poor prognosis, but in order to maintain quality of life during the patients' remaining lifespan, aggressive treatment would appear appropriate for these patients, because SCLC is a chemo-sensitive cancer.
  • [MeSH-major] Choroid Neoplasms / secondary. Lung Neoplasms / pathology. Small Cell Lung Carcinoma / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Male. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiother Oncol. 1998 Mar;46(3):263-8 [9572619.001]
  • [Cites] Gynecol Oncol. 2001 Dec;83(3):601-4 [11733980.001]
  • [Cites] Am J Ophthalmol. 1967 Apr;63(4):723-6 [6022244.001]
  • [Cites] Med Pediatr Oncol. 2000 Mar;34(3):229-30 [10696136.001]
  • [Cites] Intern Med. 1999 Jul;38(7):597-601 [10435368.001]
  • [Cites] Arch Ophthalmol. 1971 Jun;85(6):673-5 [5562786.001]
  • [Cites] Am J Ophthalmol. 2002 Sep;134(3):445-7 [12208262.001]
  • [Cites] Lung Cancer. 2007 Sep;57(3):399-403 [17397962.001]
  • [Cites] Arch Bronconeumol. 2005 Feb;41(2):99-101 [15718005.001]
  • [Cites] Am J Ophthalmol. 1983 Jun;95(6):788-93 [6859188.001]
  • [Cites] Ophthalmology. 1997 Aug;104(8):1265-76 [9261313.001]
  • (PMID = 19967493.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


12. Lewis KD, Gibbs P, O'Day S, Richards J, Weber J, Anderson C, Zeng C, Baron A, Russ P, Gonzalez R: A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF. Cancer Invest; 2005;23(4):303-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metastatic malignant melanoma remains a very difficult disease to treat.
  • Previous phase II studies using biochemotherapy (combination of platinum-containing chemotherapy with IL-2 and IFNalpha) have shown response rates of about 50%.
  • We report the results of a phase II study using a novel biochemotherapy regimen containing temozolomide, cisplatin, decrescendo IL-2, IFNalpha, and GM-CSF in the treatment of stage IV melanoma.
  • Seventy-one patients with histologically confirmed metastatic melanoma were enrolled between June 1998 and October 1999.
  • Prior chemotherapy or IL-2 was not permitted.
  • Twenty-one patients (30%) had a history of treated brain metastases.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Melanoma / drug therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Alkylating / administration & dosage. Brain Neoplasms / mortality. Brain Neoplasms / secondary. Dacarbazine / administration & dosage. Dacarbazine / analogs & derivatives. Eye Neoplasms / drug therapy. Eye Neoplasms / mortality. Eye Neoplasms / pathology. Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage. Humans. Interleukin-2 / administration & dosage. Middle Aged. Neoplasm Metastasis. Reproducibility of Results. Skin Neoplasms / drug therapy. Skin Neoplasms / mortality. Skin Neoplasms / pathology. Survival Analysis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16100942.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA46934
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Interleukin-2; 7GR28W0FJI / Dacarbazine; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; 85622-93-1 / temozolomide
  •  go-up   go-down


13. Gökmen Soysal H, Ardiç F: Malignant conjunctival tumors invading the orbit. Ophthalmologica; 2008;222(5):338-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant conjunctival tumors invading the orbit.
  • AIM: The aim of this study is to present the clinical and histopathological features as well as the treatment results of advanced conjunctival malignant tumors with orbital invasion, in the context of all secondary orbital tumors.
  • METHODS: A total of 151 secondary orbital tumors were observed over a 10-year period; 21 (14%) out of 151 cases were detected to be of conjunctival origin, and the cases were reviewed retrospectively.
  • The age, gender, duration of symptoms, clinical and histopathological features and the treatment results of patients were recorded.
  • RESULTS: Four out of 21 patients had malignant melanoma (MM), while 17 had squamous cell carcinoma (SCC) of the conjunctiva.
  • Two patients underwent wide excision with control of the surgical margins and postoperative adjunctive topical chemotherapy.
  • Two patients with regional metastasis were treated by radical neck dissection and radiation therapy to the neck.
  • After a mean follow-up time of 35.6 months, no tumor recurrence or tumor-related death was encountered.
  • Seven patients died from non-tumor-related causes.
  • CONCLUSION: Delay in presentation for treatment and previous unsuccessful surgery of conjunctival malignant lesions are likely to lead to orbital invasion and loss of the eye.
  • Exenteration is generally needed but margin-controlled wide surgical excision and adjuvant chemotherapy may be curative in selected cases.
  • Early diagnosis and effective treatment of lesions will minimize the mortality rate and morbidity related to the disease.
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness. Orbit Evisceration. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 18635931.001).
  • [ISSN] 1423-0267
  • [Journal-full-title] Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift für Augenheilkunde
  • [ISO-abbreviation] Ophthalmologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


14. Nishiura Y, Sakamoto K, Mihoki T, Takane Y, Maeda A, Miyajima Y, Nakashima T: [Autologous tumor-specific immunotherapy for recurrent malignant melanoma of the nasal cavity]. Nihon Jibiinkoka Gakkai Kaiho; 2006 Nov;109(11):781-4
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Autologous tumor-specific immunotherapy for recurrent malignant melanoma of the nasal cavity].
  • Malignant melanoma usually occurs in tissues containing large numbers of melanocytes, such as the skin, mucosa and eye, and is one of the most highly malignant tumors known.
  • No satisfactory treatment results have ever been reported.
  • We report here an effective course of immunotherapy consisting of the local injection and intra-venous administration of autologous tumor-cell-stimulated cytotoxic T lymphocytes in a patient with recurrent malignant melanoma.
  • She had been diagnosed as having malignant melanoma in 1996 and under went radio-chemotherapy at our hospital.
  • Following systematic chemotherapy, 23 local injections of cytotoxic T lymphocytes were performed.
  • Mediastinal lymphonode metastasis was recognized in March, 2004, so 15 additional intravenous administrations of cytotoxic T lymphocytes were performed.
  • Immunotherapy using cytotoxic T lymphocytes may be a useful strategy for controlling recurrent malignant melanoma.
  • [MeSH-major] Immunotherapy / methods. Melanoma / therapy. Nasal Cavity. Nose Neoplasms / therapy. T-Lymphocytes, Cytotoxic / transplantation
  • [MeSH-minor] Female. Humans. Interleukins / therapeutic use. Mediastinal Neoplasms / secondary. Mediastinal Neoplasms / therapy. Middle Aged. Neoplasm Recurrence, Local. Transplantation, Autologous. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17165592.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Interleukins
  •  go-up   go-down


15. Hasturk S, Soylu M, Zeren EH, Hanta I: Basaloid large cell lung carcinoma presenting concurrently with metastatic uveal tumor. Lung Cancer; 2001 Apr;32(1):95-101
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basaloid large cell lung carcinoma presenting concurrently with metastatic uveal tumor.
  • In his ophtalmological examination, there was total retinal detachment in the left eye.
  • Ultrasonographic examination and orbital magnetic resonance imaging (MRI) were reported as choroidal metastasis.
  • A computed tomography (CT) confirmed the mass in the left hilum and multiple mass lesions consistent with metastasis in the liver and in the body of 12th thoracic vertebra.
  • He died after 4 months with rapid progression of the disease in spite of combined chemotherapy.
  • Although primary lung cancer with concurrent eye metastasis is an uncommon entity, it should always be kept in mind for patients with ocular symptoms.
  • [MeSH-major] Carcinoma, Large Cell / pathology. Carcinoma, Large Cell / secondary. Lung Neoplasms / pathology. Uveal Neoplasms / pathology. Uveal Neoplasms / secondary
  • [MeSH-minor] Carboplatin / therapeutic use. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Paclitaxel / therapeutic use. Pleural Effusion, Malignant / pathology. Smoking / adverse effects. Tomography

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11282434.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


16. Watanabe W, Kuwabara R, Nakahara T, Hamasaki O, Sakamoto I, Okada K, Minamoto A, Mishima HK: Severe ocular and orbital toxicity after intracarotid injection of carboplatin for recurrent glioblastomas. Graefes Arch Clin Exp Ophthalmol; 2002 Dec;240(12):1033-5
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Glioblastoma is a malignant tumor that occurs in the cerebrum during adulthood.
  • With current treatment regimens including combined surgery, radiation and chemotherapy, the average life expectancy of the patients is limited to approximately 1 year.
  • Therefore, patients with glioblastoma sometimes have intracarotid injection of carcinostatics added to the treatment regimen.
  • He complained of pain and visual disturbance in the ipsilateral eye 30 h after the injection.
  • Although the intraocular pressure elevation caused by secondary acute angle-closure glaucoma decreased and ocular pain diminished, inexorable papilledema and exudative retinal detachment continued for 3 weeks.
  • Finally, 6 weeks later, diffuse chorioretinal atrophy with optic atrophy occurred and the vision in his left eye was lost.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Blindness / chemically induced. Brain Neoplasms / drug therapy. Carboplatin / adverse effects. Glioblastoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Orbital Diseases / chemically induced

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12483326.001).
  • [ISSN] 0721-832X
  • [Journal-full-title] Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie
  • [ISO-abbreviation] Graefes Arch. Clin. Exp. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin
  •  go-up   go-down


17. Katz TS, Mendenhall WM, Morris CG, Amdur RJ, Hinerman RW, Villaret DB: Malignant tumors of the nasal cavity and paranasal sinuses. Head Neck; 2002 Sep;24(9):821-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant tumors of the nasal cavity and paranasal sinuses.
  • PURPOSE: To evaluate the role of radiation therapy in patients with nasal cavity and paranasal sinus tumors.
  • MATERIALS AND METHODS: Between October 1964 and July 1998, 78 patients with malignant tumors of the nasal cavity (48 patients), ethmoid sinus (24 patients), sphenoid sinus (5 patients), or frontal sinus (1 patient) were treated with curative intent by radiation therapy alone or in the adjuvant setting.
  • Forty-seven patients were treated with irradiation alone, 25 with surgery and postoperative irradiation, 2 with preoperative irradiation and surgery, and 4 with chemotherapy in combination with irradiation with or without surgery.
  • Of the 67 (86%) patients who were initially seen with node-negative disease, 39 (58%) received no elective neck treatment, and 28 (42%) received elective neck irradiation.
  • Of the 39 patients who received no elective neck treatment, 33 (85%) did not experience recurrence in the neck compared with 25 (89%) of 28 patients who received elective neck irradiation.
  • Twenty-one (27%) of 78 patients had unilateral blindness develop secondary to radiation retinopathy or optic neuropathy; the complication was anticipated in most of these patients, because the ipsilateral eye was irradiated to a high dose.
  • CONCLUSION: Surgery and postoperative radiation therapy may result in improved local control, absolute survival, and complications when compared with radiation therapy alone.
  • [MeSH-major] Carcinoma / therapy. Nasal Cavity. Nose Neoplasms / therapy. Paranasal Sinus Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Blindness / etiology. Blindness / prevention & control. Cause of Death. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Metastasis. Neoplasm Staging. Osteoradionecrosis / etiology. Postoperative Care. Preoperative Care. Radiotherapy Dosage. Radiotherapy, Adjuvant / adverse effects. Risk Factors. Survival Rate. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley Periodicals, Inc. Head Neck 24: 821-829, 2002
  • (PMID = 12211046.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Palazzi MA, Ober MD, Abreu HF, Cardinalli IA, Isaac CR, Odashiro AN, Burnier Jr MN: Congenital uveal malignant melanoma: a case report. Can J Ophthalmol; 2005 Oct;40(5):611-5
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital uveal malignant melanoma: a case report.
  • Enucleation performed in the first weeks of life confirmed the diagnosis of diffuse uveal malignant melanoma with extraocular extension.
  • The patient was also treated with 5 cycles of chemotherapy.
  • He subsequently developed cutaneous and ocular pigmented lesions, including 2 choroidal nevi located within the posterior pole and a benign conjunctival lesion in the opposite eye, in addition to malignant melanoma of the skin.
  • We believe this represents the fourth case ever reported in the literature and the longest follow-up of a congenital malignant melanoma originating within the eye.

  • Genetic Alliance. consumer health - Uveal melanoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16391626.001).
  • [ISSN] 0008-4182
  • [Journal-full-title] Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
  • [ISO-abbreviation] Can. J. Ophthalmol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


19. Parmeggiani F, Costagliola C, D'Angelo S, Incorvaia C, Perri P, Sebastiani A: Clear cell renal cell carcinoma associated with bilateral atypical acute posterior multifocal placoid pigment epitheliopathy. Oncology; 2004;66(6):502-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/OBJECTIVE: Clear cell renal cell carcinoma (CCRCC) is a malignant neoplasm frequently associated with an increase in circulating immune complexes (CIC).
  • Acute posterior multifocal placoid pigment epitheliopathy (APMPPE) is a disease involving the chorioretinal structures of the eye, and it is commonly observed in association with several immunogenic disorders.
  • CASE REPORT: A 52-year-old white male affected by metastatic CCRCC is described.
  • RESULTS: The patient underwent total left nephrectomy (May 1997) and total left pneumonectomy (March 2001) for the presence of stage III CCRCC and CCRCC lung metastasis, respectively.
  • CONCLUSIONS: Long-standing tumorous disease, through a pathogenic mechanism triggered by CIC spreading, can be responsible, over time, for a progressive choroidal occlusive microangiopathy (atypical APMPPE pattern), associated with a high risk of poor visual outcome.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Carcinoma, Renal Cell / pathology. Choroidal Neovascularization / etiology. Kidney Neoplasms / pathology. Pigment Epithelium of Eye / pathology
  • [MeSH-minor] Angiogenesis Inhibitors / therapeutic use. Antineoplastic Agents / therapeutic use. Humans. Interferon-alpha / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Male. Middle Aged. Nephrectomy. Pneumonectomy. Vision Disorders / etiology


20. Shields CL, Honavar SG, Shields JA, Demirci H, Meadows AT, Naduvilath TJ: Factors predictive of recurrence of retinal tumors, vitreous seeds, and subretinal seeds following chemoreduction for retinoblastoma. Arch Ophthalmol; 2002 Apr;120(4):460-4
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To identify the clinical features of eyes with retinoblastomas that predict the recurrence of retinal tumors, vitreous seeds, and subretinal seeds following treatment with chemoreduction.
  • SETTING: Ocular oncology service at Wills Eye Hospital of Thomas Jefferson University (Philadelphia, Pa) in conjunction with the division of oncology at Children's Hospital of Philadelphia.
  • INTERVENTION: All patients received treatment for retinoblastoma with 6 cycles of chemoreduction using vincristine, etoposide, and carboplatin combined with focal treatment (cryotherapy, thermotherapy, or plaque radiotherapy) for each retinal tumor.
  • RESULTS: All retinal tumors, vitreous seeds, and subretinal seeds showed an initial favorable response of regression during this treatment regimen.
  • Using Kaplan-Meier estimates, at least 1 retinal tumor recurrence per eye was found in 37% of eyes at 1 year, 51% at 3 years, and no further increase at 5 years.
  • By multivariate analysis, the only factor predictive of retinal tumor recurrence was the presence of tumor-associated subretinal seeds at the initial examination.
  • By univariate analysis, the only factor predictive of vitreous seed recurrence was the presence of tumor-associated subretinal seeds at the initial examination.
  • By multivariate analysis, factors predictive of subretinal seed recurrence included a tumor base greater than 15 mm and a patient age of 12 months or younger at diagnosis.
  • There were no patients who developed retinoblastoma metastasis, pinealoblastoma, or second malignant neoplasms.
  • CONCLUSIONS: Chemoreduction combined with focal therapy is effective for selected eyes with retinoblastomas.
  • Eyes with subretinal seeds at initial examination are at particular risk for recurrence of retinal tumor and vitreous seeds.
  • Retinal tumor and subretinal seed recurrence seems to manifest within 3 years of follow-up.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / therapeutic use. Etoposide / therapeutic use. Neoplasm Recurrence, Local. Neoplasm Seeding. Retinal Neoplasms / drug therapy. Retinoblastoma / drug therapy. Vincristine / therapeutic use. Vitreous Body / pathology
  • [MeSH-minor] Combined Modality Therapy. Eye Neoplasms / secondary. Humans. Infant. Prospective Studies. Risk Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Retinoblastoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11934319.001).
  • [ISSN] 0003-9950
  • [Journal-full-title] Archives of ophthalmology (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch. Ophthalmol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; CEV regimen
  •  go-up   go-down


21. Barbón García JJ, Viña Escalar C, Menéndez Fernández CL, Fernández Alvarez C, Carballo Fernández C, Villarreal Renedo PM: [Uveal lymphoid infiltration with systemic extension]. Arch Soc Esp Oftalmol; 2003 Mar;78(3):173-6
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE REPORT: We report the case of a patient who was surgically treated in his right eye because of an uncontrollable glaucoma and a retinal detachment without retinal break.
  • Ultrasound and computed tomography showed diffuse choroidal thickening.
  • During 6 years of follow-up, he developed a major ocular and orbitary invasion and bone marrow infiltration.
  • He was treated by enucleation and chemotherapy with apparent total remission.
  • This process is regarded as a low malignant condition, but this case of late diagnosis showed a tendency to orbital and systemic extension.
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow / pathology. Cyclophosphamide / administration & dosage. Disease Progression. Doxorubicin / administration & dosage. Eye Enucleation. Glaucoma, Neovascular / etiology. Humans. Immunoglobulin kappa-Chains / blood. Male. Neoplasm Invasiveness. Orbital Neoplasms / secondary. Paraproteins. Prednisone / administration & dosage. Remission Induction. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Retinal Detachment.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12677496.001).
  • [ISSN] 0365-6691
  • [Journal-full-title] Archivos de la Sociedad Española de Oftalmología
  • [ISO-abbreviation] Arch Soc Esp Oftalmol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Immunoglobulin kappa-Chains; 0 / Paraproteins; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


22. Pache M, Kain H, Buess M, Flammer J, Meyer P: [Primary intraocular lymphoma with unusual clinical presentation and poor outcome]. Klin Monbl Augenheilkd; 2004 May;221(5):401-3
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Primäres intraokuläres Lymphom mit untypischer Klinik und ungünstigem Verlauf.
  • HISTORY AND SIGNS: A 70-year-old man was hospitalized in June 2002 because of acute loss of vision on his left eye.
  • An intraocular malignant B-cell lymphoma was determined by immunohistochemistry.
  • THERAPY AND OUTCOME: The patient initially refused any therapy until a painful secondary neovascular glaucoma with complete loss of visual function developed, thus prompting us to perform an enucleation.
  • The following immunohistochemical examination confirmed the initial diagnosis.
  • A chemotherapy with high-dose methotrexate and leucovorin rescue was initiated.
  • Diagnosis can be difficult and is often delayed.
  • [MeSH-major] Blindness / etiology. Lymphoma, B-Cell / diagnosis. Retinal Neoplasms / diagnosis
  • [MeSH-minor] Aged. Biopsy. Bruch Membrane / pathology. Chemotherapy, Adjuvant. Choroid / pathology. Choroid Neoplasms / diagnosis. Choroid Neoplasms / drug therapy. Choroid Neoplasms / pathology. Choroid Neoplasms / surgery. Combined Modality Therapy. Drug Resistance, Neoplasm. Eye Enucleation. Follow-Up Studies. Humans. Leucovorin / administration & dosage. Male. Methotrexate / administration & dosage. Optic Atrophy / pathology. Prognosis. Retina / pathology. Vitrectomy. Vitreous Body / pathology. Vitreous Hemorrhage / diagnosis. Vitreous Hemorrhage / pathology. Vitreous Hemorrhage / surgery

  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15162291.001).
  • [ISSN] 0023-2165
  • [Journal-full-title] Klinische Monatsblätter für Augenheilkunde
  • [ISO-abbreviation] Klin Monbl Augenheilkd
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down






Advertisement